Characteristics and usage of icarelatumumab concentrated solution for injection

Epcoritumab (Epcoritamab) is a targeted bispecific antibody drug used to treat a specific type of B cell non-Hodgkin lymphoma . Its dosage form is a concentrated solution for injection. The drug is administered by subcutaneous injection, which is more convenient in clinical operations than traditional intravenous infusion, helping to improve patient compliance and reduce infusion-related adverse events during treatment. The pharmaceutical properties, storage methods and usage of Epcoritab Concentrated Solution for Injection must strictly follow the drug instructions and clinical regulations.

From the perspective of the physical and chemical properties of the drug,Epcoritamab is a clear to slightly milky sterile concentrated solution. It should be avoided to be mixed with other drugs for injection, and medicinal solutions that have precipitated, changed color or become turbid should not be used. Each injection contains a specified concentration of active ingredients and stable excipients and must be operated at room temperature by professional medical personnel in accordance with standard procedures. No dilution is required before use, the corresponding dose should be drawn directly from the original packaging. When Epcoritamab is administered, the dose must be gradually titrated according to a plan to reduce the risk of cytokine release syndrome (CRS). This dose escalation strategy is called a "dose escalation lead-in period" and is usually carried out within the first few weeks, after which a fixed maintenance dose phase can be entered.

In terms of usage, the drug needs to be given by subcutaneous injection. The injection site is usually selected in the abdominal area to avoid scar tissue, redness, itching or broken skin. The entire injection process needs to be monitored in a medical institution by medical staff with experience in immunotherapy, and symptomatic treatment drugs to deal with acute allergic reactions and immune side effects must be prepared. At the beginning of treatment, it is recommended that patients be observed for no less than a few hours in order to promptly respond to possible CRS or infusion reactions. The injection cycle is generally once a week, and depending on the condition and efficacy evaluation, it can be gradually adjusted to a maintenance treatment plan of once every two weeks or every four weeks.

Reference materials:https://www.drugs.com/epcoritamab.html